Source facts
FDA issued an approval letter for ZITUVIMET on 2026-04-28. The source metadata identifies NDA 216743 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
ZITUVIMET — FDA Approval Letter (NDA 216743)
Issued to ZYDUS LIFESCIENCES. Application is approved as submitted.
Issued
April 28, 2026Application
NDA 505b1 • 216743
Product
ZITUVIMET
Company
ZYDUS LIFESCIENCES
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for ZITUVIMET?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 216743.
- 3Submission: supplement.
- 4Sponsor: ZYDUS LIFESCIENCES.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the ZITUVIMET approval letter
Is ZITUVIMET FDA approved?
This letter documents an FDA approval action: FDA approved NDA 216743 for ZITUVIMET, sponsored by ZYDUS LIFESCIENCES, on April 28, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 216743?
NDA 216743 is the application under which FDA issued this approval letter for ZITUVIMET to ZYDUS LIFESCIENCES. The letter is dated April 28, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.